Experienced in Immune Thrombocytopenic Purpura (ITP)

Dominique Dive

Liege, WAL, BE 
Experienced in Immune Thrombocytopenic Purpura (ITP)
Liege, WAL, BE 
OverviewLocationsClinical Research

Overview

Dominique Dive practices in Liege, Belgium. Dive is rated as an Experienced expert by MediFind in the treatment of Immune Thrombocytopenic Purpura (ITP). Their top areas of expertise are Multiple Sclerosis (MS), Adult Immune Thrombocytopenia, CACH Syndrome, and Immune Thrombocytopenic Purpura (ITP).

Their clinical research consists of co-authoring 27 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Immune Thrombocytopenic Purpura (ITP).

Locations

Liege, WAL, Belgium
Other Locations
Lodelinsart, WAL, Belgium
Esneux, WAL, Belgium
Brussels, BRU, Belgium
Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Evaluating the Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS: An Exploratory Phase IV Ambispective Study of Patients Who Previously Participated in the CLARITY/CLARITY-EXT and ORACLE MS Clinical Trials (CLASSIC-MS)
Evaluating the Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS: An Exploratory Phase IV Ambispective Study of Patients Who Previously Participated in the CLARITY/CLARITY-EXT and ORACLE MS Clinical Trials (CLASSIC-MS)
Enrollment Status: Completed
Publish Date: October 31, 2023
Intervention Type: Other
Study Drug: Cladribine
Study Phase: Phase 4
A 2-year Prospective Study to Evaluate the Onset of Action of Mavenclad® in Subjects With Highly Active Relapsing Multiple Sclerosis (MAGNIFY)
A 2-year Prospective Study to Evaluate the Onset of Action of Mavenclad® in Subjects With Highly Active Relapsing Multiple Sclerosis (MAGNIFY)
Enrollment Status: Completed
Publish Date: March 16, 2023
Intervention Type: Drug
Study Drug: Mavenclad®
Study Phase: Phase 4
View 1 Less Clinical Trial

27 Total Publications

European experience of cladribine tablets in elderly patients with multiple sclerosis: Could it be the last treatment?
European experience of cladribine tablets in elderly patients with multiple sclerosis: Could it be the last treatment?
Journal: Multiple sclerosis journal - experimental, translational and clinical
Published: December 12, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dive's expertise for a condition
ConditionClose
      View All 12 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile